GLS expects further growth in the medical field with micro-needle technology

March. 28. 2022
Settings
2022-03-28 08:59
GLS expects further growth in the medical field with micro-needle technology
![]() |
Endoderma cosmetic product sold by GLS in Europe / Courtesy of Endoderma |
By Kim Jae HeunGLS, a European business partner of Endoderma, is grateful to work with the Korean bio-enterprise company, which it believes holds great potential for medical use.
“The patented technology is truly impressive and leads to top-notch, science-backed products. We are proud to be on this journey as partners and to represent this technology especially for the European market,” said the GLS CEO Benedikt Burkhardt during an interview with The Korea Times on March 16.
Endoderma’s micro-needle technology, which delivers medication by attaching a patch with fine needles to the body, has enormous potential for different types of uses. This is especially true for cosmetic purposes, but the potential medical use of such innovative technology is also looming on the horizon.
“The technology bridges the gap between injections and dermal application, for example creams. I think that explains the huge potential of micro-needle technology,” Burkhardt said.
Burkhardt sees huge potential for this relatively young technology, which has already gained industry acceptance.
“As always, new application forms need to create trust and that takes time. However, Endoderma’s technology is already very well accepted and we see great potential for growth in the medical field. With the right partners in the good segments, this application form can be extremely efficient and useful for many people,” Burkhardt said. “GLS is grateful to share mutual values with Endoderma such as trust, transparency and hard work to deliver excellent products with maximum effect to customers.”